Assessing Bruker: Insights From 6 Financial Analysts

Ratings for Bruker (NASDAQ:BRKR) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.

	Bullish	Somewhat Bullish	Indifferent	Somewhat Bearish	Bearish
Total Ratings	1	3	2	0	0
Last 30D	0	1	0	0	0
1M Ago	0	0	0	0	0
2M Ago	1	2	2	0	0
3M Ago	0	0	0	0	0

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $45.17, a high estimate of $60.00, and a low estimate of $38.00. This current average represents a 11.73% decrease from the previous average price target of $51.17.

Decoding Analyst Ratings: A Detailed Look

The standing of Bruker among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst	Analyst Firm	Action Taken	Rating	Current Price Target	Prior Price Target
Luke Sergott	Barclays	Lowers	Overweight	$40.00	$43.00
Brandon Couillard	Wells Fargo	Lowers	Overweight	$50.00	$60.00
Daniel Arias	Stifel	Lowers	Hold	$40.00	$48.00
Patrick Donnelly	Citigroup	Lowers	Neutral	$38.00	$40.00
Luke Sergott	Barclays	Lowers	Overweight	$43.00	$46.00
Brandon Couillard	Jefferies	Lowers	Buy	$60.00	$70.00

Key Insights:

• Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Bruker. This insight gives a snapshot of analysts' perspectives on the current state of the company.
• Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Bruker compared to the broader market.
• Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Bruker's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.

Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Bruker's market standing. Stay informed and make data-driven decisions with our Ratings Table.

Stay up to date on Bruker analyst ratings.

Discovering Bruker: A Closer Look

Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.

Understanding the Numbers: Bruker's Finances

Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.

Decline in Revenue: Over the 3M period, Bruker faced challenges, resulting in a decline of approximately -0.41% in revenue growth as of 30 June, 2025. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Bruker's net margin is impressive, surpassing industry averages. With a net margin of 0.95%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): Bruker's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 0.42%, the company may encounter challenges in delivering satisfactory returns for shareholders.

Return on Assets (ROA): Bruker's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.12%, the company may face hurdles in achieving optimal financial performance.

Debt Management: With a high debt-to-equity ratio of 1.35, Bruker faces challenges in effectively managing its debt levels, indicating potential financial strain.

The Basics of Analyst Ratings

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.